)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
HilleVax
HilleVax (HLVX) investor relations material
HilleVax has been acquired
HilleVax Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary6 Aug, 2025
Executive summary
Entered into a definitive merger agreement with XOMA Royalty, with shareholders to receive $1.95 per share in cash plus a contingent value right; closing anticipated in September 2025.
Tender offer expected to commence by August 18, 2025.
Terminated the Takeda License for HIL-214, effective six months after August 1, 2025.
Workforce reduced by 80% during 2024, with only 12 full-time employees as of August 4, 2025.
Report covers the quarter ended June 30, 2025, focusing on vaccine development and strategic alternatives after discontinuing HIL-214 in infants.
Financial highlights
Net loss was $5.3 million for Q2 2025, compared to $40.7 million for Q2 2024.
Net loss for the six months ended June 30, 2025 was $11.3 million, down from $87.5 million for the same period in 2024.
Cash, cash equivalents, and marketable securities totaled $159.5 million as of June 30, 2025, down from $171.4 million at year-end 2024.
Research and development expenses fell to $1.3 million in Q2 2025 from $26.6 million in Q2 2024; for the six months, R&D dropped to $3.3 million from $52.6 million year-over-year.
General and administrative expenses fell to $11.3 million from $16.6 million year-over-year for the six-month period.
Outlook and guidance
Existing cash and equivalents expected to fund operations for at least the next 12 months.
No revenue expected until successful development and approval of vaccine candidates, which is not anticipated in the near term.
Pending merger with XOMA may impact future operations and capital allocation.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from HilleVax
- Failed trial led to $113.3M loss, 55% staff cuts, and focus on new vaccine strategies.HLVX
Q3 2024 - Net loss widened, 40% workforce cut, and focus shifted to adult vaccine candidates.HLVXQ2 2024
- Q1 2025 net loss fell to $6.1M as costs dropped and strategic options were pursued.HLVXQ1 2025
- 2024 net loss reached $147.3M as HilleVax pursues strategic options for its vaccine pipeline.HLVXQ4 2024
HilleVax
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
HilleVax, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines. The company’s primary product under development is HIL-214, a virus-like particle-based vaccine candidate aimed at preventing moderate-to-severe acute gastroenteritis caused by norovirus infection. HilleVax has been working on advancing this vaccine through clinical trials, with efforts to evaluate its safety and efficacy across different age groups. Hillevax is headquartered in Boston, Massachusetts, and its shares are listed on the NASDAQ.